Biome Technologies rated at a fraction of projected revenues, says Edison
http://www.proactiveinvestors.co.uk/companies/news/32814/biome-technologies-rated-at-a-fraction-of-projected-revenues-says-edison-32814.html
Biome Technologies (LON:BIOM) is growing a profitable bioplastics operation yet it is being rated at a fraction of its projected revenues, according to City research house Edison.
Following the publication of the firm's first-half results last week, Edison, in an upbeat note, says Biome has taken further strides towards a break-even position - with progress made in each division.
Although Edison is not currently projecting break even before full year 2013, it has raised its estimates following the first half results and further upgrades are not out of the question, noted analyst Toby Thorrington.
For full year 2011, Edison has raised its estimates (or reduced the expected pre-tax loss) by around 0.3 million, said the analyst.
For the first half this year to June 30, Biomes revenues increased 55 per cent to 10.4 million (HI 2010: 6.7 million), with the operating loss reduced to 0.4 million (H1 2010: 1.2 million loss).
The firm's main activity is the development and sale of biodegradable natural polymers that replace and enhance products made conventionally from oil-based materials through its Bioplastics division. This includes two companies: Southampton-based Biome Bioplastics and Biotec.
Biome Bioplastics is responsible for the marketing and distribution of Biomes bioplastic products, as well as research and development, while Biotec acts as the firms manufacturing unit.
The company also owns Stanelco RF Technologies - a legacy business that designs, builds and services advanced radio frequency systems.
"Biome delivered improved revenues and associated contributions from all three of its constituent companies, with increasing acceptance of its bioplastic formulations being particularly notable," said Thorrington.
"Careful management restricted cash outflow in the period and left a reasonable cash position from which to reach an overall group profit position on a realistic time horizon," he added.
Edison said that Biome's share price had underperformed the wider market (-20 percent compared to -14 percent) since its note on May 11 about the company.
Edison reckons that the firm's key Biome Bioplastics business is being valued at just one third of FY11 sales - growing faster than previously anticipated.
"The profit model is not yet proven, but the company is moving more rapidly towards this position," said the note